利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.027 秒)

    Nitroxyl progenitors in the treatment of heart failure
    1.
    发明申请
    Nitroxyl progenitors in the treatment of heart failure 有权
    硝基脯氨酸治疗心力衰竭

    公开(公告)号：US20050192254A1

    公开(公告)日：2005-09-01

    申请号：US11096924

    申请日：2005-03-31

    申请人： David Wink ,  Martin Feelisch ,  David Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

    发明人： David Wink ,  Martin Feelisch ,  David Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

    IPC分类号： A61K31/13 ,  A61K31/16 ,  A61K31/655 ,  A61K31/137

    CPC分类号： A61K31/655 ,  A61K31/13 ,  A61K31/16 ,  A61K33/00 ,  A61K2300/00

    摘要： Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO(Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO+ donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.

    摘要翻译： 施用HNO / NO - 辅助化合物，例如Angeli盐，增加心肌收缩力，同时降低经历心力衰竭的受试者的左心室预负荷。 此外，给予HNO / NO - 供体化合物异丙胺（IPA）/ NO（Na（CH 3）2 CHNHN（O）NO ）令人惊讶地在经历心力衰竭的受试者中表现出正向的变力作用，其优于由提供HNO /供体化合物Angeli盐引起的那些。 另外，与使用NO + +供体观察到的效果相反，与正性肌力药物组合施用HNO / NO + - 供体不会损害正性肌力作用 正性肌力药。 此外，HNO / NO 发挥其与肾上腺素能系统无关的正性肌力作用，即使在接受β-拮抗剂治疗的受试者中也增加收缩力。

    Nitroxyl Progenitors in the Treatment of Heart Failure
    2.
    发明申请
    Nitroxyl Progenitors in the Treatment of Heart Failure 审中-公开
    硝酸基因祖细胞治疗心力衰竭

    公开(公告)号：US20110081427A1

    公开(公告)日：2011-04-07

    申请号：US12949533

    申请日：2010-11-18

    申请人： David A. Wink ,  Martin Feelisch ,  David A. Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

    发明人： David A. Wink ,  Martin Feelisch ,  David A. Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

    IPC分类号： A61K33/00 ,  A61P9/04 ,  A61K31/655

    CPC分类号： A61K31/655 ,  A61K31/13 ,  A61K31/16 ,  A61K33/00 ,  A61K2300/00

    摘要： Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO− donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.

    摘要翻译： 施用HNO / NO供体化合物，例如Angeli盐可增加心肌收缩力，同时降低心衰患者的左心室预负荷。 此外，HNO / NO供体化合物异丙胺（IPA）/ NO（Na（CH 3）2 CHNHN（O）NO）的给药令人惊讶地在经历心力衰竭的受试者中表现出优于HNO / NO- 捐赠化合物Angeli的盐。 另外，与使用NO-供体观察到的效果相反，将HNO / NO供体与正性肌力药物联合给药不会损害正性肌力药物的正性肌力作用。 此外，HNO / NO-不依赖于肾上腺素能系统发挥其正性肌力作用，即使在接受β-拮抗剂治疗的受试者中也能增加收缩力。

    Nitroxyl progenitors in the treatment of heart failure
    3.
    发明授权
    Nitroxyl progenitors in the treatment of heart failure 有权
    硝基脯氨酸治疗心力衰竭

    公开(公告)号：US07863262B2

    公开(公告)日：2011-01-04

    申请号：US11096924

    申请日：2005-03-31

    申请人： David A. Wink ,  Martin Feelisch ,  David A. Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

    发明人： David A. Wink ,  Martin Feelisch ,  David A. Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

    IPC分类号： A01N51/00 ,  A61K31/655 ,  A61K31/13 ,  A61K33/26

    CPC分类号： A61K31/655 ,  A61K31/13 ,  A61K31/16 ,  A61K33/00 ,  A61K2300/00

    摘要： Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO(Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO− donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.

    摘要翻译： 施用HNO / NO供体化合物，例如Angeli盐可增加心肌收缩力，同时降低心衰患者的左心室预负荷。 此外，HNO / NO供体化合物异丙胺（IPA）/ NO（Na（CH 3）2 CHNHN（O）NO）的给药令人惊讶地在经历心力衰竭的受试者中表现出优于HNO / NO- 捐赠化合物Angeli的盐。 另外，与使用NO-供体观察到的效果相反，将HNO / NO供体与正性肌力药物联合给药不会损害正性肌力药物的正性肌力作用。 此外，HNO / NO-不依赖于肾上腺素能系统发挥其正性肌力作用，即使在接受β-拮抗剂治疗的受试者中也能增加收缩力。

    Nitroxyl progenitors in the treatment of heart failure
    4.
    发明授权
    Nitroxyl progenitors in the treatment of heart failure 有权
    硝基脯氨酸治疗心力衰竭

    公开(公告)号：US06936639B2

    公开(公告)日：2005-08-30

    申请号：US10226412

    申请日：2002-08-21

    申请人： David A. Wink ,  Martin Feelisch ,  David A. Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

    发明人： David A. Wink ,  Martin Feelisch ,  David A. Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

    IPC分类号： A61K31/13 ,  A61K31/16 ,  A61K31/19

    CPC分类号： A61K31/655 ,  A61K31/13 ,  A61K31/16 ,  A61K33/00 ,  A61K2300/00

    摘要： Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO− donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy

    摘要翻译： 施用HNO / NO - 辅助化合物如Angeli盐可增加心肌收缩力，同时降低经历心力衰竭的受试者的左心室预负荷。此外，给予HNO / 供体化合物异丙胺（IPA）/ NO（Na（CH 3 3）2 CHNHN（O）NO）令人惊讶地在经历心力衰竭的受试者中表现出正性肌力作用 由HNO / NO - 捐赠化合物Angeli的盐引起的那些。 另外，与使用NO-SUP供体观察到的效果相反，将HNO / NO + - 供体与正性肌力药物组合给药不会损害正性肌力作用 正性肌力药物另外，HNO / NO 发挥其与肾上腺素能系统无关的正性肌力作用，即使在接受β-拮抗剂治疗的受试者中也增加收缩力

    Thiol-Sensitive Positive Inotropes
    7.
    发明申请
    Thiol-Sensitive Positive Inotropes 审中-公开
    硫醇敏感正性Inotropes

    公开(公告)号：US20090298795A1

    公开(公告)日：2009-12-03

    申请号：US11922793

    申请日：2006-06-23

    申请人： Nazareno Paolocci ,  David A. Kass ,  Carlo G. Tocchetti

    发明人： Nazareno Paolocci ,  David A. Kass ,  Carlo G. Tocchetti

    IPC分类号： A61K31/655 ,  A61K31/18

    CPC分类号： A61K33/00 ,  A61K31/13 ,  A61K31/135 ,  A61K31/185 ,  A61K31/655 ,  C12Q1/6818

    摘要： The present invention relates to methods for treating diastolic dysfunction or a disease, disorder or condition associated with diastolic dysfunction, methods for treating heart failure, methods for modulating SR Ca2+ release and/or uptake, methods for enhancing myocyte relaxation, preload or E2P hydrolysis, and methods for treating ventricular hypertrophy.

    摘要翻译： 本发明涉及用于治疗舒张功能障碍或与舒张功能障碍相关的疾病，病症或病症的方法，用于治疗心力衰竭的方法，用于调节SR Ca 2+释放和/或摄取的方法，用于增强肌细胞松弛，预加载或E2P水解的方法， 和治疗心室肥大的方法。